Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA/CD70 CAR-T cells in refractory systemic lupus erythematosus
NCT07318259Phase 1Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Jan 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCMA/CD70 CAR-T cells in systemic lupus erythematosus (SLE), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety of CAR-T cell therapy at 3 months, Systemic Lupus Erythematosus Disease Activity Index 2000 at 6 months and 5 more. Started Jan 2026; status: recruiting.
02
Drugs
BCMA/CD70 CAR-T cells
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07318259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318259.